Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL7081988 | 1.00 | ALDH1A1 (0.59) | ALDH1A1NPSR1RXFP1KDM4EPRNP | |
| Quinoline SCHEMBL4747553 | 0.90 | ALDH1A1 (0.55) | ALDH1A1NPSR1RXFP1KDM4EPRNP | |
| Quinoline SCHEMBL5874361 | 0.88 | ALDH1A1 (0.61) | ALDH1A1NPSR1RXFP1KDM4EPRNP | |
| Quinoline SCHEMBL27820159 | 0.88 | ALDH1A1 (0.61) | ALDH1A1NPSR1RXFP1KDM4EPRNP | |
| Quinoline SCHEMBL5874375 | 0.88 | ALDH1A1 (0.61) | ALDH1A1NPSR1RXFP1KDM4EPRNP | |
| Oxyquinoline SCHEMBL28087250 | 0.87 | ALDH1A1 (0.57) | ALDH1A1KDM4ESMN1; SMN2LMNAMEN1 | |
| Quinoline SCHEMBL4265433 | 0.85 | ALDH1A1 (0.68) | ALDH1A1KDM4ESMN1; SMN2LMNAALOX15 | |
| Quinoxaline SCHEMBL28009513 | 0.85 | NPSR1 (0.46) | ALDH1A1NPSR1RXFP1KDM4EPRNP | |
| Quinoline SCHEMBL5272119 | 0.85 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2PABPC1ALOX15 | |
| Quinoline SCHEMBL2201840 | 0.85 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2PABPC1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106047846-A | An 8-hydroxyquinoline alanine translation system and applications thereof | 中国科学院生物物理研究所 | 2016-10-26 | — | — | CN | claimed |
| CN-104059891-B | 8-hydroxyquinoline alanine translation system and application thereof | 中国科学院生物物理研究所 | 2016-08-17 | — | — | CN | claimed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| EP-3921331-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020160685-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2020-08-13 | — | — | WO | disclosed |
| CN-103122024-B | AntiHIV1 RT activity infection polypeptide, composition and the purposes of engineer | 中国人民解放军军事医学科学院毒物药物研究所 | 2017-12-29 | — | — | CN | disclosed |
| CN-106047846-A | An 8-hydroxyquinoline alanine translation system and applications thereof | 中国科学院生物物理研究所 | 2016-10-26 | — | — | CN | disclosed |
| CN-104059891-B | 8-hydroxyquinoline alanine translation system and application thereof | 中国科学院生物物理研究所 | 2016-08-17 | — | — | CN | disclosed |
| EP-1322616-A2 | QUINOLINE-(C=O)-(DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002018341-A9 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYST PROD INC (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | MP BIOMEDICALS, LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | ALDH1A1 1872/4885NPSR1 17/4885RXFP1 23/4885 |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | CASP3, CASP1, BAX | ALDH1A1 1648/4885NPSR1 3170/4885RXFP1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.